Scancell Holdings (SCLP)

 

SCLP Share PerformanceMore

52 week high16.950 24/08/17
52 week low9.675 11/05/17
52 week change -1.000 (-6.90%)
4 week volume7,348,162 22/01/18
price13.500
price date1518797759
close14.500

Media for (SCLP)

Presenter: Dr Richard Goodfellow
30/07/2015
Presenter: Dr Richard Goodfellow
01/06/2015

Latest NewsMore

Scancell to present at the Calculus Investor Forum

RNS Number: 0690F Scancell Holdings Plc 16 February 2018 16 February 2018 Scancell Holdings Plc ("Scancell" or the "Company") Scancell to present at the Calculus Investor Forum Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that Cliff Holloway, Chief Executive Officer and Lind...

Scancell signs agreement with ISA Pharmaceuticals

Scancell, a developer of novel immunotherapies for the treatment of cancer, has signed a worldwide licensing and collabor...

Hardman Res. - Validating multiple opportunities

RNS Number: 9320E Scancell Holdings Plc 15 February 2018 Hardman Research - Validating multiple opportunities Validating and de-risking of multiple opportunities: Scancell is a clinical-stage biotechnology company developing two distinct flexible cancer immunotherapy platforms, each with broad applications: ImmunoBody is a DNA vaccine that stimulates high...

Collaboration agreement with ISA Pharmaceuticals

RNS Number: 9322E Scancell Holdings Plc 15 February 2018 ISA Pharmaceuticals and Scancell enter collaboration agreement for the manufactur ing , development and commerciali s ation of Modi-1 / AMPLIVANT combination AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019 Collaboration seeks to further leverage Moditope platform Leiden, The ...

Scancell collects positive results from cancer treatment trial

Scancell Holdings said it continued to collect positive results from patient trials for a cancer treatment. Overall, 18 of 20 stag...

Publication highlights potential of SCIB1 therapy

RNS Number: 5035E Scancell Holdings Plc 12 February 2018 12 February 2018 Scancell Holdings Plc ("Scancell" or the "Company") Peer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients Compelling 5-year survival data with most resected stage III and IV patients remaining alive Phase 2 trial anticipated to start in H2 2018 Scancell Hold...

Trends and Targets for 12/02/2018

FTSE THIS WEEK (FTSE:UKX) We should find a way of building our articles which gives folks an idea of which bit to r...

Scancell patent application for Moditope granted in Europe

Scancell Holdings said the European Patent Office had announced an intention to grant Scancell's patent application for its...

Fundamental DataMore

EPS-1.36
Dividend yield0 %

Latest discussion posts More

Users' HoldingsMore

Users who hold Scancell Holdings also hold..

Codes & Symbols

ISINGB00B63D3314
SymbolsSCLP, LSE:SCLP, SCLP.L, SCLP:LN, LON:SCLP, XLON:SCLP

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account